Abstracts tagged "osteoarthritis and quality of life"

Abstract Number: 1366 • 2018 ACR/ARHP Annual Meeting
Assessment of Health-Related Quality of Life in a 52-Week, Phase 2, Randomized, Controlled Trial of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Treatment of Knee Osteoarthritis
Vibeke Strand¹, Heli Ghandehari², Christopher Swearingen² and Jeyanesh Tambiah², ¹Stanford University School of Medicine, Palo Alto, CA, ²Samumed, LLC, San Diego, CA
Background/Purpose: SM04690, a small molecule, intra-articular (IA) Wnt pathway inhibitor, is in development for knee OA treatment. A phase 2, 52-week, trial evaluated changes in…
Abstract Number: 918 • 2012 ACR/ARHP Annual Meeting
Impact of Comorbidities On Measuring Indirect Utility by the Medical Outcomes Study Short Form 6D in Lower-Limb Osteoarthritis
Kossar Hosseini¹, Cécile Gaujoux-Viala², Joel Coste³, Jacques Pouchot¹, Bruno Fautrel⁴, Anne-Christine Rat⁵ and Francis Guillemin¹, ¹Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, F- 54 000, France, Nancy, France, ²Rheumatology, Montpellier I University, Nîmes University Hospital, Nîmes, France, ³Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁴Rheumatology, UPMC - Paris 6 University, Paris, France, ⁵Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France
Background/Purpose: Comorbidities refer to chronic co-occuring disorders and are inversely and negatively correlated with HRQoL. Because indirect utility measurement involves HRQoL, comorbidities probably affect utility…
Abstract Number: 243 • 2012 ACR/ARHP Annual Meeting
Relationship of Physical Activity with Health Utility in the Osteoarthritis Initiative
Dorothy D. Dunlop¹, Jing Song¹, Rowland W. Chang², Jungwha Lee³, Pamela A. Semanik⁴, Linda S. Ehrlich-Jones⁵, Kai Sun⁶, Leena Sharma⁷, C. Kent Kwoh⁸, Charles Eaton⁹ and Larry Manheim¹⁰, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Dept Preventive Med, Northwestern University, Chicago, IL, ³Preventive Medicine, Northwestern University, Chicago, IL, ⁴Rehabilitation Institute Chicago, Oak Park, IL, ⁵Research CROR, Rehabilitation Institute Chicago, Chicago, IL, ⁶Medicine, Northwestern University, Chicago, IL, ⁷Division of Rheumatology, Northwestern University, Chicago, IL, ⁸School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, ¹⁰Institute Healthcare Studies, Northwestern University, Chicago, IL
Background/Purpose: Cost effectiveness analyses of arthritis interventions require utility measurements to evaluate their relative effectiveness. Clinical guidelines for knee osteoarthritis (KOA) treatment include a substantial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].